|
|
|
20.05.26 - 07:01
|
Interim Report for the period January – March 2026 (Cision)
|
|
|
Strong financial performance with commercial milestone reached
Events during the first quarter 2026
· Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment
· Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks
· The application for marketing authorization for subcutaneous initiation treatment with Leqembi was granted Priority Review in China
· New long‑term and real‑world data for Leqembi, presented at the AD/PD™ conference in...
|
|
|
|
|
|
|
|
|
|
|
15.05.26 - 08:36
|
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 – March 2027) (Cision)
|
|
|
Stockholm, Sweden, May 15, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 2026 (April 2026 through March 2027), corresponding to a 63 percent growth compared to the previous year. This would generate approximately SEK 880 M in royalty to BioArctic during the same period.
Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor...
|
|
|
|
|
08.05.26 - 09:06
|
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S. (Cision)
|
|
|
Stockholm, Sweden, May 8, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi® Iqlik™, as a starting dose for the treatment of early Alzheimer's disease. The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026.
As part of the ongoing review process, the agency requested additional information and has...
|
|
|
08.05.26 - 08:51
|
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S. (PR Newswire)
|
|
|
STOCKHOLM, May 8, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly......
|
|
|
|
|
|
|
29.04.26 - 12:00
|
Leqembi® annual sales exceed EUR 500 million – second sales milestone achieved (Cision)
|
|
|
Stockholm, Sweden, April 29, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the global sales of Leqembi surpassed EUR 500 million in Eisai's fiscal year 2025 (April 2025 – March 2026), triggering a second sales-related milestone payment of EUR 20 million to BioArctic.
Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for...
|
|
|
29.04.26 - 12:00
|
Sales of Leqembi® totaled 26.2 billion yen in the first quarter 2026 (Cision)
|
|
|
Stockholm, Sweden, April 29, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the first quarter 2026, in conjunction with their partner Biogen's first quarter report. In total, sales of JPY 26.2 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 161 million, which is an increase of approximately 68 percent compared to the royalty recorded by BioArctic for the first quarter 2025.
Eisai's results for their fourth quarter and full year FY2025 (April 2025 - March 2026)...
|
|
|
|
|
21.04.26 - 15:00
|
Tortugas Neuroscience Launches with $106 Million to Advance Clinical Stage Pipeline Targeting New and Major Neurology and Neuropsychiatric Disorders (Business Wire)
|
|
|
Biotech Veterans Jeff Jonas and Al Robichaud to Lead Company with Investment from Cure Ventures, The Column Group, and AN VenturesFRAMINGHAM, Mass.--(BUSINESS WIRE)--#ANVentures--Tortugas Neuroscience (“Tortugas”), a neurology-focused biotech company developing novel medicines with derisked mechanisms of actions, for large and well-defined indications, today announces $106 million in Seed and Series A financings. The funding will support ongoing research and development initiatives, including the completion of Phase 2 clinical trials for its two lead candidates.
Founding investor Cure Ventures, a life sciences venture capital firm focusing on de novo company formation around groundbreaking technologies, led the Seed round, and will co-lead the Series A round along with The Column Group and AN Venture Partners.
In-licensed from Eisai Co., Ltd. (Tokyo, Japan) and Jiangsu Hansoh Pharmaceutical Group Ltd. (Greater China), the clinical stage pipeline includes potential treatments for schizophrenia, tinnitu...
|
|
|
|
|
26.03.26 - 23:48
|
XFRA: DIVIDEND/INTEREST INFORMATION - 30.03.2026 - JP3160400002 (XETRA)
|
|
|
Das Instrument EII JP3160400002 EISAI CO. LTD EQUITY wird cum Dividende/Zinsen gehandelt am 27.03.2026 und ex Dividende/Zinsen am 30.03.2026
The instrument EII JP3160400002 EISAI CO. LTD EQUITY has its pre-dividend/interest day on 27.03.2026 and its ex-dividend/interest day on 30.03.2026...
|
|
|
|
|
|
|
25.03.26 - 04:54
|
Research Team Confirms Safety of Alzheimer′s Drug Lecanemab (Nippon)
|
|
|
Tokyo, March 25 (Jiji Press)--More than 90 pct of patients receiving Lecanemab, an Alzheimer's drug, in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers in the country said. Lecanemab, developed by Eisai Co. and Biogen Inc. and put on sale in December 2023, removes amyloid beta from the brain to slow the progress of Alzheimer's ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
